

CURRENT REPORT 6/2023

January 20th, 2022

Admission and introduction of the series J shares of the Company to trading on the regulated market of the WSE

The Management Board of Ryvu Therapeutics S.A. with its registered office in Kraków ("Issuer"), with reference to current report No. 6/2023 of January 20th, 2023 informs that on January 20th, 2023 the Management Board of the Warsaw Stock Exchange S.A. adopted Resolution No. 51/2023 on the admission and the introduction to exchange trading on the main market of the WSE of series J ordinary bearer shares of the Company, pursuant to which the Management Board of the Warsaw Stock Exchange S.A. stated that 4,764,674 (four million seven hundred sixty-four thousand six hundred seventyfour) series J ordinary bearer shares of the Issuer with a nominal value of PLN 0.40 each with ISIN code PLSELV00013 ("Series J Shares") are admitted to exchange trading on the main market.

The WSE Management Board decided to introduce on January 25th, 2023 the Series J Shares to exchange trading on the main market, subject to the registration of the Series J Shares by the National Depository for Securities S.A. with the ISIN code PLSELV00013 on January 25th, 2023.

Legal basis: Article 56.1.2 of the Act on Public Offering, Current and periodic information

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board